Clinical Trials Logo

Lymphomatoid Papulosis clinical trials

View clinical trials related to Lymphomatoid Papulosis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03409432 Active, not recruiting - Clinical trials for Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Start date: March 16, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well brentuximab vedotin and lenalidomide work in treating patients with stage IB-IVB T-cell lymphoma that have come back or do not respond to treatment. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin and lenalidomide may work better in treating patients with T-cell lymphoma.

NCT ID: NCT01352520 Active, not recruiting - Lymphoma Clinical Trials

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Start date: June 2011
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if SGN-35 (brentuximab vedotin) can help to control ALCL, LyP or MF in patients with at least 1 of the 3 skin lymphomas. The safety of the study drug will also be studied.